Madrigal Pharmaceuticals-Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates

Madrigal (MDGL) came out with a quarterly loss of $7.10 per share versus the Zacks Consensus Estimate of a loss of$ 7.55. This compares to loss of $4.69 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.96%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 6.06 per share when it actually produced a loss of $7.38, delivering a surprise of -21.78%. Over the last four quarters, the company ...